CollPlant Biotechnologies (FRA:CPT) Ending Cash Position: €3.69 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CPT CollPlant Biotechnologies Ltd FRA:CPT
27 GF Score
Price €0.27
GF Value €0.24
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies Ending Cash Position?

CollPlant Biotechnologies FRA:CPT 27 Ending Cash Position is €3.69 Mil as of Mar. 2026. GuruFocus rates FRA:CPT with a GF Score™ of 27/100 and a GF Value™ of €0.24 (Modestly Overvalued). The stock has 4 warning signs investors should review.

CollPlant Biotechnologies's Ending Cash Position for the quarter that ended in Mar. 2026 was €3.69 Mil.

CollPlant Biotechnologies's quarterly Ending Cash Position declined from Sep. 2025 (€7.28 Mil) to Dec. 2025 (€4.78 Mil) and declined from Dec. 2025 (€4.78 Mil) to Mar. 2026 (€3.69 Mil).

CollPlant Biotechnologies's annual Ending Cash Position declined from Dec. 2023 (€24.46 Mil) to Dec. 2024 (€11.37 Mil) and declined from Dec. 2024 (€11.37 Mil) to Dec. 2025 (€4.78 Mil).

CollPlant Biotechnologies Ending Cash Position Related Terms

CollPlant Biotechnologies Ending Cash Position Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies Ending Cash Position Chart

CollPlant Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.84 28.19 24.46 11.37 4.78

CollPlant Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.93 9.91 7.28 4.78 3.69
FRA:CPT
27GF Score
CollPlant Biotechnologies Ltd FRA:CPT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CollPlant Biotechnologies Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CollPlant Biotechnologies's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=10.171+-5.396
=4.78

CollPlant Biotechnologies's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.836+-1.149
=3.69

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €3.69 Mil mean?
CollPlant Biotechnologies (FRA:CPT) has a Ending Cash Position of €3.69 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CollPlant Biotechnologies and its competitors.
Is CollPlant Biotechnologies' Ending Cash Position too high?
CollPlant Biotechnologies' current Ending Cash Position is €3.69 Mil. Overall, CollPlant Biotechnologies has a GF Score™ of 27/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Ending Cash Position compare to XBIO and JUNS?
CollPlant Biotechnologies' Ending Cash Position of €3.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current Ending Cash Position is €3.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €0.27 — trading 10.8% above its estimated fair value. The current Ending Cash Position is €3.69 Mil. CollPlant Biotechnologies' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current Ending Cash Position is €3.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of €0.27 is trading 10.8% above its estimated GF Value™ of €0.24. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for FRA:CPT:

  • Ending Cash Position: €3.69 Mil
  • GF Value™: €0.24 vs. price of €0.27 (10.8% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Other Exchanges CLGN:USA
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
27GF Score

Get the complete analysis for FRA:CPT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.24
GF Value